Krystal Biotech (NASDAQ:KRYS) Receives "Buy" Rating from HC Wainwright

Key Points

• Krystal Biotech's stock received a "Buy" rating from HC Wainwright with a price target of $240.00, indicating a potential upside of 55.59% from its previous close.
• The company reported a net margin of 40.85% and earnings per share (EPS) of $1.29, which surpassed analysts' expectations of $1.08.
• Insider activity includes the sale of 1,389 shares by Suma Krishnan, amounting to approximately $208,350, reflecting a 0.09% decrease in ownership.

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $240.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 55.59% from the company's previous close.

A number of other brokerages also recently weighed in on KRYS. Citigroup reiterated a "neutral" rating and issued a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Chardan Capital reduced their price target on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Finally, Bank of America reduced their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Moderate Buy" and an average price target of $209.00.

Krystal Biotech Trading Up 7.4%

KRYS stock traded up $10.58 during mid-day trading on Monday, reaching $154.26. 454,399 shares of the stock traded hands, compared to its average volume of 328,081. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $207.84. The company has a market cap of $4.46 billion, a P/E ratio of 31.35 and a beta of 0.66. The stock's fifty day moving average is $146.81 and its 200-day moving average is $152.43.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The company had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Equities research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Activity

In related news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the transaction, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 49,800 shares of company stock valued at $7,487,943 in the last ninety days. 13.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. State Street Corp grew its stake in Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company's stock valued at $186,306,000 after purchasing an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. increased its stake in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock worth $126,870,000 after acquiring an additional 481,200 shares during the period. Braidwell LP boosted its stake in Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company's stock valued at $100,045,000 after buying an additional 327,067 shares in the last quarter. Geode Capital Management LLC grew its position in Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company's stock valued at $85,174,000 after acquiring an additional 7,194 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Krystal Biotech by 173.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after acquiring an additional 365,304 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.